Aurora Borealis May Hit These 16 States Over the Next Two Days
Of the two days, Tuesday night into Wednesday morning will be your best shot. The Space Weather Prediction Center is forecasting a Kp 5 magnetic storm that's scheduled to hit over six hours starting late Monday evening. The K-Index measures the horizontal impact of geomagnetic storms, and a Kp 5 rating results in what NOAA calls a "moderate" aurora.
Things will calm down a bit Wednesday night going into Thursday morning, with the aurora pulling back a bit and being less visible unless you're on the northern border with Canada. NOAA is forecasting a Kp 4 magnetic storm that night.
NOAA predicts the northern lights reaching into the US on Tuesday and Wednesday.
NOAA
Which states could see the aurora borealis?
Per the Space Weather Prediction Center, Tuesday night's aurora will be visible in Washington state, Idaho, Montana, Wyoming, North and South Dakota, Minnesota, Iowa, Wisconsin, Michigan, and the northernmost sections of New York, Vermont, New Hampshire, and most of Maine.
Alaska and Canada will have the best views by a wide margin, with the entire state of Alaska getting coverage. Technically, there will also be a slice of Oregon, putting the full number at 16, but unless you live on the northeastern tip, you likely won't see anything.
Much like Earth's weather, space weather prediction can be hit or miss. So, if you're in any of the above states, it's worth taking a look if you're up that late. It may be slightly stronger or weaker than forecasted, which will affect how far south the northern lights reach. It won't be as strong as the epic show we saw in May 2024.
Tips on viewing the northern lights
The standard space viewing tips all apply here. You'll get a better view if you get away from the city and suburbs to avoid light pollution. Weather will play a role as well, since clouds will obfuscate the view. If you attempt to photograph the aurora, we recommend using long exposure times to give your camera more time to soak in the light.
Other than that, you'll want to look toward the northern horizon to give yourself the best chance at a good view since that's where the northern lights originate.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Scientists Find Popular Vitamin Targets Visible Signs of Aging, Makes Skin Look Younger
Vitamin C may help support the health of the epidermis, the outermost layer of skin. Getting adequate levels of vitamin C may help fight signs of skin aging, according to recent findings. Doctors explain how to get more of the essential vitamin in your diet. Your skin protects your body from germs and other environmental hazards, but it gets weaker over time. That changes its appearance, leading to visible signs of aging, like wrinkles and fine lines. While you can't do anything to stop your skin from getting older, new research suggests that vitamin C may help skin look younger. Specifically, having plenty of vitamin C in your diet may help to reactivate certain genes that control your skin's growth and repair. The study, which was published in the Journal of Investigative Dermatology, used lab-grown models designed to mimic human skin. In these models, the skin cells were exposed to air while being nourished underneath with a liquid nutrient designed to mimic the way your skin gets nutrients from your blood vessels. Meet the experts: Gary Goldenberg, M.D., assistant clinical professor of dermatology at Icahn School of Medicine at Mount Sinai Hospital; Ife J. Rodney, M.D., founding director of Eternal Dermatology + Aesthetics The researchers used vitamin C at different concentrations comparable to what would be transported from your bloodstream to the epidermis, which is the outermost layer of your skin. After seven days, the researchers discovered that the skin that was treated with vitamin C had a thicker epidermal cell layer without impacting the stratum corneum, which is the outer layer of skin made up of dead cells. After two weeks, the epidermis was thicker, while the outer layer of dead skin cells was thinner. This suggests that vitamin C helps to boost the formation and division of keratinocytes, skin cells that move from deeper layers of the skin to the surface, the researchers explained. The researchers also found that skin samples that were treated with vitamin C had more cell proliferation, which is important for maintaining the skin's healthy barrier and creating a fresher look. 'Vitamin C is a promising molecule that can be used as a developing treatment for epidermal thinning, including in aging,' the researchers wrote in the conclusion. The findings raise questions about the impact of vitamin C on skin. So, should we all be having more of it in our lives for a healthier, younger-looking complexion? Here's what dermatologists want you to keep in mind. Vitamin C, a.k.a. L-ascorbic acid, is a water-soluble vitamin. Humans need to get vitamin C from food and supplements, making it a vital part of the diet, according to the National Institutes of Health (NIH). Vitamin C plays a role in several areas of health, including biochemical reactions to support collagen and protein metabolism, per the NIH. Vitamin C also helps with wound healing and is an antioxidant that supports immune function. Most adult women need 65 to 75 milligrams of vitamin C a day, while most adult men need 75 to 90 milligrams daily. While many adults in the U.S. get the recommended amounts of vitamin C daily from foods and drinks, some are more at risk of not getting enough than others, per the NIH. Those include: People who smoke and are exposed to second-hand smoke. People who eat a limited diet. People with certain medical conditions, like severe malabsorption, certain types of cancer, and some forms of kidney disease. When you eat or drink something with vitamin C, it's absorbed into your bloodstream and then transported to the skin, explains Gary Goldenberg, M.D., assistant clinical professor of dermatology at Icahn School of Medicine at Mount Sinai Hospital. There, it tends to be concentrated in the basal layer of the epidermis, which is the deepest layer of the outer layer of your skin. Vitamin C is a co-factor (meaning it's a required element) in a process that activates genes that are involved in cell proliferation, Dr. Goldenberg says. 'This can lead to epidermal thickening and improved skin health and appearance,' he says. Vitamin C is also crucial for the production of collagen, a protein that helps to support your skin's barrier and enhances your skin's elasticity, says Ife J. Rodney, M.D., founding director of Eternal Dermatology + Aesthetics. 'Collagen is the building block of the skin,' she says. 'It's the supporting matrix that gives the skin its tightness and firmness, but over the years, it starts to break down. That's why skin gets saggy and thin.' While having more vitamin C in your life won't magically transform your skin, it can help, Dr. Rodney says. If you eat a lot of vitamin C-rich foods, Dr. Goldenberg says you should get enough of the nutrient to support good skin health. If you could do better, these are some of the most vitamin C-rich foods to consider eating, per the NIH: Red bell pepper, ½ cup: 95 milligrams Orange juice, ¾ cup: 93 milligrams Orange, 1 medium: 70 milligrams Grapefruit juice, ¾ cup: 70 milligrams Kiwifruit, 1 medium: 64 milligrams Green pepper, ½ cup: 60 milligrams Broccoli, ½ cup: 51 milligrams If you're not sure how you're doing on the vitamin C front or if you're concerned that you may not be absorbing the nutrient properly, Dr. Goldenberg says a blood test can help determine your levels. 'If levels are low or not optimal, supplementation can help,' he says. However, Dr. Rodney points out that vitamin C supplements aren't for everyone. 'They really don't help unless you're deficient,' she says. This study focused on having vitamin C in your diet, but dermatologists say there's a role for vitamin C serums in skincare, too. 'I like topical vitamin C on the skin—serums, specifically,' Dr. Rodney says. Because of vitamin C's antioxidant effect, these can help to protect the skin from environmental stressors, she says, which may contribute to signs of aging. (Dr. Rodney recommends looking for a serum with vitamin C and ferulic acid, which helps keep the vitamin C molecule stable in your products.) Overall, dermatologists say the findings stress the importance of eating a healthy diet for good skin health. 'Nutrition has a direct impact on skin health,' Dr. Goldenberg says. 'Nutrients like vitamin C can promote skin regeneration, delay aging effects, and maintain barrier function.' Dietary supplements are products intended to supplement the diet. They are not medicines and are not intended to treat, diagnose, mitigate, prevent, or cure diseases. Be cautious about taking dietary supplements if you are pregnant or nursing. Also, be careful about giving supplements to a child, unless recommended by their healthcare provider. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
an hour ago
- Yahoo
Satellite backed by Google, Bezos and Musk to track methane is lost in space
An $88mn satellite backed by Google, Jeff Bezos and Elon Musk's SpaceX has been lost in space, in a blow to global efforts to detect the Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David Putrino are key thought leaders in the clinical and translational biology of Long COVID and Post-Vaccination Syndrome Initial SPEAR clinical efforts to be aimed at rigorous, controlled assessment of monoclonal antibody safety, translational biology, and exploratory efficacy in relevant patient populations characterized by persistent virus or circulating SARS-CoV-2 spike protein WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group, with leading investigators focused on the biology and clinical disease or injury associated with chronic exposure to SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the SPEAR Study Group was initiated in response to a growing number of case reports and reported case series from across the U.S. suggesting meaningful symptom relief / remission of Long COVID following use of PEMGARDA® (pemivibart), a monoclonal antibody currently authorized by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. While these emerging reports are anecdotal and uncontrolled, they collectively support a longstanding, mechanistically plausible hypothesis: that prolonged exposure to pathogenic SARS-CoV-2 spike protein or other forms of persistent virus or viral material may drive disease in some patients, and that reducing this burden through monoclonal antibody therapy may offer a promising therapeutic approach worthy of rigorous clinical investigation. Clinical research to be planned by the SPEAR Study Group is critical to exploring disease biology and evaluating efficacy endpoints that can enable registrational studies if appropriate in the future. The SPEAR Study Group includes the following investigators and researchers who, along with Invivyd, will collaborate on the design and anticipated execution of relevant clinical trials: Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco Amy Proal, Ph.D., Co-Founder and CEO, Polybio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ('CoRE') David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ('CoRE') and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai. The SPEAR Study Group intends to launch collaborative, multi-center translational clinical research on Long COVID, including PVS, as soon as practicable, including use of next-generation monoclonal antibody candidates from Invivyd such as VYD2311. 'It is now clear from a growing body of high-quality, peer-reviewed research that persistent spike protein or viral reservoirs can be identified in a meaningful portion of people with Long COVID,' said Dr. Peluso. 'For the first time in years, there is a company with the capability to explore this space using active, broadly neutralizing monoclonal antibodies. This research marks an essential step toward understanding what may cause debilitating COVID-driven chronic disease, and we hope will lay the groundwork for future efficacy studies that could deliver real therapeutic options to patients who have waited far too long.' 'Long COVID is a pervasive, debilitating, and underappreciated public health challenge affecting millions of adults and children in the U.S., with no approved treatments,' said Marc Elia, Chairman of the Board at Invivyd. 'Monoclonal antibodies have already demonstrated efficacy in preventing acute COVID-19 infections and treating acute COVID-19 infections, including long-term infections, and emerging anecdotal reports suggest pemivibart may have potential in addressing symptoms in some Long COVID patients. We believe that monoclonal antibodies are key to managing the ongoing burden of endemic COVID-19 disease in all forms, and as previously disclosed, we will be meeting with the FDA early in 3Q to discuss rapid approval pathways for COVID-19 mAbs. Meanwhile, our formation of the SPEAR Study Group is a critical step toward potentially unlocking a Long COVID treatment opportunity for patients in need by generating data needed to inform future studies and potential regulatory pathways. We look forward to sharing future milestones as we advance this important initiative.' About PEMGARDA PEMGARDA® (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells. PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19, treatment of Long COVID, or post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse reactions included systemic infusion-related reactions and hypersensitivity reactions, local infusion site reactions, and infusion site infiltration or extravasation. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning. To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies. About VYD2311 VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd's proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd's investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd's investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit to learn more. Trademarks are the property of their respective owners. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'could,' 'expects,' 'estimates,' 'intends,' 'potential,' 'predicts,' 'projects,' and 'future' or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, expectations regarding the SPEAR Study Group and its anticipated goals; the plans of the SPEAR Study Group to structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein mAb therapy in people suffering from Long COVID or PVS; expectations regarding Long COVID prevalence and burden in the U.S.; statements about the potential of mAb therapy to offer a therapeutic approach to Long COVID; expectations regarding the capability of Invivyd to explore the Long COVID space; whether pemivibart may have potential in addressing symptoms in some Long COVID patients; the potential of the SPEAR Study Group research to lay groundwork for future efficacy studies; the company's expectation to share future milestones regarding the SPEAR Study Group initiative; expectations regarding engagement between Invivyd and the FDA; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents who have moderate-to-severe immune compromise; the potential of VYD2311 as a novel mAb candidate; the company's devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the SPEAR Study Group, and the company's discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company's product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart and VYD2311 targets remains structurally intact; whether the company's product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; whether mAb therapy is able to offer a therapeutic approach to Long COVID; the ability to gain alignment with the applicable regulatory authorities on clinical trial designs and regulatory pathways for COVID-19 mAbs, and the timing thereof; changes in the regulatory environment; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; future clinical trial site activation or enrollment rates; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revised or revoked by the FDA; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in expected or existing competition; the company's reliance on third parties; complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; the company's ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Contacts: Media Relations(781) 208-1747media@ Investor Relations(781) 208-1747investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
